Clinical Intervention Study in the Primary Care Setting of Patients With High Plasma Fibrinogen (EFAP)

This study has been completed.
Sponsor:
Collaborator:
SCMFIC FAMILY DOCTORS CATALAN SOCIETY GRANT
Information provided by:
Jordi Gol i Gurina Foundation
ClinicalTrials.gov Identifier:
NCT01089530
First received: February 10, 2010
Last updated: March 17, 2010
Last verified: March 2010
  Purpose

Objectives:

  • To study the possible effects of an intensive lifestyle change program on, the plasma fibrinogen levels in patients with no cardiovascular disease, with a high fibrinogen and normal cholesterol levels, and moderate Cardiovascular Risk (CVR).
  • To analyse whether or not the effect on fibrinogen is independent of the effect on lipids.

Methods: Controlled, randomised clinical trial in 13 Basic Health Areas (BHA) in L'Hospitalet de Llobregat (Barcelona) and Barcelona city. Of the 436 patients between 35 and 75 years with no cardiovascular disease, with a high plasma fibrinogen (> 300 mg/dl) and a plasma cholesterol < 250 mg/dl, 218 received a more frequent and intensive intervention, consisting of advice on lifestyle changes and treatment. The follow up frequency of the intervention group was every two months. The other 218 patients continued with their usual care in the BHAs. Fibrinogen, plasma cholesterol and other clinical biochemistry parameters were assessed.


Condition Intervention
Cardiovascular Risk Factors
Behavioral: Lifestyle intensive group

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Clinical Intervention Study in the Primary Care Setting of Patients With High Plasma Fibrinogen in Primary Prevention of Cardiovascular Disease

Resource links provided by NLM:


Further study details as provided by Jordi Gol i Gurina Foundation:

Primary Outcome Measures:
  • To evaluate the effect of an intensive intervention to modify lifestyle (hypocaloric diet, smoking cessation and physical exercise) in the fibrinogen levels. [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess the effect of this intensive intervention in some modifiable cardiovascular risk factors. [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 436
Study Start Date: January 2003
Estimated Study Completion Date: December 2006
Arms Assigned Interventions
No Intervention: Standard care Behavioral: Lifestyle intensive group
hipocaloric diet smoking cessation physical exercise

  Eligibility

Ages Eligible for Study:   35 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged between 30 and 75 years, than in 2 analytical consecutive, separated by a minimum interval of 15 days, have fibrinogen plasma > 300 mg/dl and plasma Total cholesterol < 250 mg/dl.
  • Acceptance through informed consent of the patient to participate in the study.

Exclusion Criteria:

  • Patients receiving lipid lowering treatment (including dietary measures)
  • Local or generalized, acute or chronic infection.
  • Patients with a history of cardiovascular disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01089530

Locations
Spain
ABS Florida Sud
L'Hospitalet del Llobregat, Barcelona, Spain, 08905
Sponsors and Collaborators
Jordi Gol i Gurina Foundation
SCMFIC FAMILY DOCTORS CATALAN SOCIETY GRANT
  More Information

No publications provided

Responsible Party: Jordi Gol i Gurina, IDIAP
ClinicalTrials.gov Identifier: NCT01089530     History of Changes
Other Study ID Numbers: P03/07
Study First Received: February 10, 2010
Last Updated: March 17, 2010
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Jordi Gol i Gurina Foundation:
Fibrinogen
Cholesterol
Cardiovascular risk factors
Primary prevention
High levels fibrinogen
High plasma fibrinogen

ClinicalTrials.gov processed this record on September 18, 2014